Effect of Intraperitoneal Neutrophils Induced by OK432 on Malignant Ascites

[1]  S. Nakahara,et al.  Dendritic cells stimulated with a bacterial product, OK-432, efficiently induce cytotoxic T lymphocytes specific to tumor rejection peptide. , 2003, Cancer research.

[2]  H. Yoshida,et al.  Enhancement of anti-tumor immunity by lipoteichoic acid-related molecule isolated from OK-432, a streptococcal agent, in athymic nude mice bearing human salivary adenocarcinoma: role of natural killer cells. , 2002, Anticancer research.

[3]  Y. Ohashi,et al.  Efficacy of Adjuvant Immunochemotherapy With OK-432 for Patients With Curatively Resected Gastric Cancer: A Meta-Analysis of Centrally Randomized Controlled Clinical Trials , 2002, Journal of immunotherapy.

[4]  F. Tanaka,et al.  Effective strategy of dendritic cell-based immunotherapy for advanced tumor-bearing hosts: the critical role of Th1-dominant immunity. , 2002, Molecular cancer therapeutics.

[5]  M. Mai,et al.  Evaluation of Intraoperative Intraperitoneal Cytology for Advanced Gastric Carcinoma , 2002, Oncology.

[6]  A. Hagiwara,et al.  Tumor cytotoxicity of peritoneal macrophages induced by OK-432 , 2001, Anti-cancer drugs.

[7]  H. J. Yu,et al.  Results of immunochemo-surgery for gastric carcinoma. , 2001, Hepato-gastroenterology.

[8]  M. Mai,et al.  Streptococcal preparation OK-432 enhances the antitumor activity of CPT-11 by increasing Th1-cytokine production in mice. , 2001, Anticancer research.

[9]  Y. Ohashi,et al.  Meta-analysis of Adjuvant Immunochemotherapy Using OK-432 in Patients With Resected Non-Small-Cell Lung Cancer , 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

[10]  K. Orita,et al.  The prognostic advantage of preoperative intratumoral injection of OK-432 for gastric cancer patients , 2001, British Journal of Cancer.

[11]  T. Shiraishi,et al.  Multi-institutional randomized clinical study on the comparative effects of intracavital chemotherapy alone versus immunotherapy alone versus immunochemotherapy for malignant effusion , 1999, British Journal of Cancer.

[12]  Y. Yamaguchi,et al.  Down-regulation of IL-10 enhances the efficacy of locoregional immunotherapy using OK-432 against malignant effusion. , 1999, Anticancer research.

[13]  H. Yoon,et al.  OK‐432 and 5‐fluorouracil, doxorubicin, and mitomycin C (FAM‐P) versus FAM chemotherapy in patients with curatively resected gastric carcinoma , 1998, Cancer.

[14]  T. Morisaki,et al.  The past, the present and future of the OK-432 therapy for patients with malignant effusions. , 1998, Anticancer research.

[15]  X Chen,et al.  Streptococcal preparation OK-432 is a potent inducer of IL-12 and a T helper cell 1 dominant state. , 1997, Journal of immunology.

[16]  K. Nomoto,et al.  The concurrent administration of OK432 augments the antitumor vaccination effect with tumor cells by sustaining locally infiltrating natural killer cells , 1996, Cancer Immunology, Immunotherapy.

[17]  M. Akashi,et al.  Anti‐cancer agent OK432 induces manganese superoxide dismutase in human granulocytes , 1996, International journal of cancer.

[18]  A. Araki,et al.  The neutrophil as an information transmitter in tumor inhibition by a streptococcal biological response modifier, OK-432 , 1996, Cancer Immunology, Immunotherapy.

[19]  S. Meijer,et al.  Effect of intraperitoneal administration of granulocyte/macrophage-colony-stimulating factor in rats on omental milky-spot composition and tumoricidal activity in vivo and in vitro , 1996, Cancer Immunology, Immunotherapy.

[20]  T. Morisaki,et al.  Induction of inflammatory cytokines in effusion cavity by OK-432 injection therapy for patients with malignant effusion: role of interferon-gamma in enhancement of surface expression of ICAM-1 on tumor cells in vivo. , 1996, Clinical immunology and immunopathology.

[21]  T. Himoto,et al.  Combination immunotherapy with OK-432, recombinant granulocyte-colony-stimulating factor and recombinant interleukin-2 for human hepatocellular carcinoma , 1996, Cancer Immunology, Immunotherapy.

[22]  S. Matsuoka,et al.  Combination chemo-immunotherapy of murine solid tumor with OK-432, G-CSF, IL-2, and chemotherapeutics. , 1995, International journal of immunopharmacology.

[23]  Y. Yamaguchi,et al.  Locoregional immunotherapy of malignant ascites by intraperitoneal administration of OK-432 plus IL-2 in gastric cancer patients. , 1995, Anticancer research.

[24]  H. Wakimoto,et al.  Cytokine-gene-modified tumor vaccination intensified by a streptococcal preparation OK-432 , 1995, Cancer Immunology, Immunotherapy.

[25]  H. Ueoka,et al.  OK-432 induces production of neutrophil chemotactic factors in malignant pleural effusion. , 1995, Internal medicine.

[26]  Y. Maehara,et al.  Postoperative immunochemotherapy including streptococcal lysate OK-432 is effective for patients with gastric cancer and serosal invasion. , 1994, American journal of surgery.

[27]  T. Yoshida,et al.  OK-432-induced enhancement of ICAM-1 expression on tumor cells positively correlates to therapeutic effects for malignant effusion. , 1994, Clinical immunology and immunopathology.

[28]  K. Matsushima,et al.  Induction of inflammatory cytokines in the pleural effusion of cancer patients after the administration of an immunomodulator, OK-432: role of IL-8 for neutrophil infiltration. , 1993, Cytokine.

[29]  A. Hagiwara,et al.  Activation of omental milky spots and milky spot macrophages by intraperitoneal administration of a streptococcal preparation, OK-432. , 1992, Cancer research.

[30]  Pan‐Chyr Yang,et al.  Comparison of OK‐432 and mitomycin C pleurodesis for malignant pleural effusion caused by lung cancer. A Randomized Trial , 1992, Cancer.

[31]  Toshio Takahashi,et al.  Cellular subsets of the milky spots in the human greater omentum , 1991, Cell and Tissue Research.

[32]  T. Watanabe,et al.  Mechanism of tumoricidal activity of OK-432-specific L3T4+ Lyt2- T-cells. , 1990, Cancer research.

[33]  N. Ishida,et al.  Adoptive immunotherapy by pantropic killer cells recovered from OK-432-injected tumor sites in mice. , 1988, Cancer research.

[34]  K. Kanazawa,et al.  Milky spots (taches laiteuses) as structures which trap asbestos in mesothelial layers and their significance in the pathogenesis of mesothelial neoplasia , 1979, International journal of cancer.

[35]  S. Shoin,et al.  Studies on the anticancer and streptolysin S-forming abilities of hemolytic streptococci. , 1967, Japanese journal of microbiology.

[36]  Kuender D Yang,et al.  Effect of picibanil (OK432) on neutrophil-mediated antitumor activity: Implication of monocyte-derived neutrophil-activating factors , 2005, Cancer Immunology, Immunotherapy.

[37]  K. Ryoyama.  Effector molecules from antitumor macrophages induced with OK-432 and cyclophosphamide , 2005, Cancer Immunology, Immunotherapy.

[38]  K. Naito,et al.  Cytokine-mediated antitumor effect of OK-432 on urinary bladder tumor cells in vitro , 2004, Urological Research.

[39]  Y. Maehara,et al.  Postoperative chemotherapy including intraperitoneal and intradermal administration of the streptococcal preparation OK-432 for patients with gastric cancer and peritoneal dissemination: a prospective randomized study , 2004, Cancer Chemotherapy and Pharmacology.

[40]  H. Yoshida,et al.  Cytokine-inducing activity and antitumor effect of a liposome-incorporated interferon-gamma-inducing molecule derived from OK-432, a streptococcal preparation. , 2000, Journal of immunotherapy.

[41]  I. Splichal,et al.  Induction of inflammatory cytokines by Nocardia fractions. , 1993, Folia biologica.

[42]  R. Beelen,et al.  Milky spots in the mouse omentum may play an important role in the origin of peritoneal macrophages. , 1992, Research in immunology.

[43]  T. Yadomae,et al.  Oral administration of a streptococcal agent OK-432 activates peritoneal macrophages in mice. , 1991, International journal of immunopharmacology.

[44]  M. Torisu,et al.  New approach to management of malignant ascites with streptococcal preparation OK-432. III. OK-432 attracts natural killer cells through a chemotactic factor released from activated neutrophils. , 1990, Surgery.